Use with caution when in combination with other centrally acting drugs and alcohol Concomittant administratin with antihypertensives can potentiate hypotension It antagonozes the effects of levodopa and dopamine agonists Concomittant administration with drugs like omeprazole and rifampicin may increase the olazapine clearance rate Inhibitors of CYP1A2 (eg. fluvoxamine ) inhibits its elimination Carbamazepine therapy causes an increase in the clearance of olanzapine

Mild , transcient antimuscarinic effects, agitation, behavoiural problems, Chest pain, fever, Flu-like symptoms, Inability to move eyes, Lip smacking, mood changes, Giddiness, loss of memory, Nervousness, puffung of cheeks, Swelling of feet or ankles, Changes in menstrualperiod, Hyperprolactinemia

Hypersensitivity, angle-closure glaucoma, breast feeding

Special precautions:

Should be used cautiously in patients with a history of seizures, Alzhemers dementia, aspiration pneumonia, pregnancy, hepatic impairment, renal impairment, and depression

Date of Approval     2000

Indications

Schizophrenia

Dosage:

10mg daily adjusted toi usual range of 5-20 mg daily, doses of 15mg daily or greater only after reassessment

Pharmacology:

Olanzapine is selective-monoaminergic antagonist with high affinity binding to receptors like sertonin, dopamine, muscarinic,histamine and adrenergic receptors.

Olanzapine binds weakly to GABA, BZD, and beta adrenergic receptors The proposed mechanism of action for antipychotic activity is mediated through a combination of dopamine and serotinin type antagonism.

Pregnancy Not recommended for use during pregnancy Breast feeding Contraindicated